Phase 2a clinical trial of ATI-450 in an additional immuno-inflammatory indication.
Latest Information Update: 13 May 2020
At a glance
- Drugs Zunsemetinib (Primary)
- Indications Immunological disorders; Inflammation
- Focus Therapeutic Use
- Sponsors Aclaris Therapeutics
- 13 May 2020 New trial record